A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
Principal Investigator
Study Number
STUDY02001294
Summary
This study is looking at the effectiveness of an experimental drug (not FDA approved yet) to decrease the worsening of disabling symptoms of primary progressive multiple sclerosis. Every participant has 2 chances out of 3 to be taking the experimental drug. Likewise, every participant has 1 chance out of 3 to be taking placebo (a pill that does not contain any medication, experimental or otherwise). All participants will take experimental drug or placebo for a minimum of 24 months, but could be taking drug or placebo for as many as 48 months. Some of the participants taking placebo who experience 6-month confirmed disease progression, may be switched to the experimental drug as a rescue treatment. And, all participants who compete the study and are taking the experimental medication at the end of the study will be offered the chance to continue on the experimental drug for 24 more months so that more information about the drug can be collected.
Phase
III
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms